A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence
F1000Research · 05.09.2024 · 13 · 781
DOI: 10.12688/f1000research.153243.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, online erschienen am 05.09.2024. Verfasst von Riham Ayoubi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H…. Hauptthemen laut MEDLINE: Immunoprecipitation, Casein Kinase II, Fluorescent Antibody Technique, Blotting, Western. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Simons Foundation Autism Research Initiative, Genome Canada, from Canadian Institutes of Health Research Foundation.
Abstract (Originalsprache)
Casein kinase II subunit alpha (CSNK2A1), a serine/threonine kinase, phosphorylates multiple protein substrates and is involved in diverse cellular and biological processes. Implicated in various human diseases, high-performing antibodies would help evaluate its potential as a therapeutic target and benefit the scientific community. In this study, we have characterized ten CSNK2A1 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H3A 2B4, Canada.
ORCID-Profile: Charles Alende, Vera Ruíz Moleón, Kathleen Southern, Carl Laflamme
Förderung
- Simons Foundation Autism Research Initiative
- Genome Canada
- from Canadian Institutes of Health Research Foundation
- Genome Quebec
- Mitacs
- Ontario Genomics
Zitieren
APA
Ayoubi, R., Fotouhi, M., Alende, C., Ruíz Moleón, V., Southern, K., Laflamme, C., NeuroSGC/YCharOS/EDDU collaborative group, & ABIF consortium (2024). A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence. F1000Research, 13, 781. https://doi.org/10.12688/f1000research.153243.2
Vancouver
Ayoubi R, Fotouhi M, Alende C, Ruíz Moleón V, Southern K, Laflamme C, et al. A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence. F1000Research. 2024;13:781. doi:10.12688/f1000research.153243.2
BibTeX
@article{Ayoubi2024,
author = {Ayoubi, Riham and Fotouhi, Maryam and Alende, Charles and Ruíz Moleón, Vera and Southern, Kathleen and Laflamme, Carl and NeuroSGC/YCharOS/EDDU collaborative group, NeuroSGC/YCharOS/EDDU collaborative group and ABIF consortium, ABIF consortium},
title = {A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence},
journal = {F1000Research},
year = {2024},
volume = {13},
pages = {781},
doi = {10.12688/f1000research.153243.2}
}
EUVIMED